問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

鄭富銘
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

76Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭富銘

List

89Cases

2025-03-01 - 2028-04-30

Phase I

Active
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    Subcutaneous injection Capsule

Participate Sites
4Sites

Recruiting4Sites

2025-06-01 - 2027-09-30

Phase III

Active
A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator's Choice in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent BTK Inhibitors

  • Condition/Disease

    Chronic Lymphocytic Leukemia 、Small Lymphocytic Lymphoma

  • Test Drug

    Tablets

Participate Sites
5Sites

Recruiting5Sites

2025-11-11 - 2030-12-31

Phase II/III

Active
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

  • Condition/Disease

    Cachexia 、Metastatic Pancreatic Ductal Adenocarcinoma

  • Test Drug

    Injectable

Participate Sites
5Sites

Not yet recruiting5Sites

2025-10-01 - 2030-12-31

Phase I

Active
A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies

  • Condition/Disease

    Diffuse Large B-Cell Lymphoma、 Chronic Lymphocytic Leukemia、 B Cell Malignancies、 Non-Hodgkin's Lymphoma

  • Test Drug

    N/A

Participate Sites
3Sites

Recruiting3Sites

2025-11-01 - 2030-12-31

Phase III

Active
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Prostatic Neoplasms, Castration-Resistant

  • Test Drug

    Infusion fluid Infusion fluid Tablets

Participate Sites
5Sites

Recruiting5Sites

2025-11-07 - 2029-09-25

Phase III

Not yet recruiting
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Injectables

Participate Sites
8Sites

Recruiting8Sites

2025-12-01 - 2033-05-05

Phase III

Not yet recruiting
FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration

  • Condition/Disease

    Carcinoma, Transitional Cell、 Urinary Bladder Neoplasms 、Neoplasm Metastasis

  • Test Drug

    N/A

Participate Sites
10Sites

Recruiting5Sites

2023-08-01 - 2032-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-09-01 - 2027-05-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-04-10 - 2026-10-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB